Strategies in immunosuppression after heart transplantation is less better?

Circulation: Heart Failure

Volumn 4, Issue 2, 2011, Pages 111-113

  Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Editorials; Heart transplantation; Immunosuppression; Outcome studies; Transplantation

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ANGIOCARDIOGRAPHY; CARDIAC GRAFT REJECTION; DRUG WITHDRAWAL; EDITORIAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; BIOPSY; CORONARY ARTERY DISEASE; DRUG COMBINATION; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; METHODOLOGY; NOTE; PATHOLOGY; TIME;

ADRENAL CORTEX HORMONES; BIOPSY; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955932904     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.960690     Document Type: Editorial

References (20)

1. Baran D, Zucker MJ, Arroyo LH, Camacho M, Goldschmidt ME, Nicholls SJ, Prevost-Fernandez J, Carr C, Adams L, Pardi S, Hou V, Binetti M, McCahill J, Chichetti J, Viloria V, Sanagustin MG, Ebuenga-Smith J, Mele L, Martin A, Blicharz D, Wolski K, Olesnicky L, Qian F, Gass AL, Cohen M. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: The Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) trial. Circ Heart Fail. 2011;4:129-137.
2. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa JA, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710-1720. (Pubitemid 41641841)
3. Meiser B, Kaczmarek I, Mueller M, Groetzner J, Weis M, Knez A, Stempfle HU, Klauss V, Schmoeckel M, Reichart B, Ueberfuhr P. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J Heart Lung Transplant. 2007;26:598-603. (Pubitemid 46818048)
4. Rosenbaum DH, Adams BC, Mitchell JD, Jessen ME, Paul MC, Kaiser PA, Pappas PA, Meyer DM, Wait MA, Drazner MH, Yancy CW, Ring S, DiMaio JM. Effects of early steroid withdrawal after heart transplantation. Ann Thorac Surg. 2006;82:637-644. (Pubitemid 44088648)
5. Lee KF, Pierce JD, Hess ML, Hastillo AK, Wechsler AS, Guerraty AJ. Cardiac transplantation with corticosteroid-free immunosuppression: Long-term results. Ann Thorac Surg. 1991;52:211-217, discussion 8.
6. Yacoub M, Alivizatos P, Khaghani A, Mitchell A. The use of cyclosporine, azathioprine, and anti-thymocyte globulin with or without low-dose steroids for immunosuppression of cardiac transplant patients. Transplant Proc. 1985;17:221-222. (Pubitemid 15170797)
7. Kobashigawa JA, Stevenson LW, Brownfield ED, Moriguchi JD, Kawata N, Fandrich R, Drinkwater DC, Laks H. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant. 1992;11: 428-430.
8. Olivari MT, Jessen ME, Baldwin BJ, Horn VPH, Yancy CW, Ring WS, Rosenblatt RL. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant. 1995;14:127-135.
9. Felkel TO, Smith AL, Reichenspurner HC, LaFleur B, Lutz JF, Kanter KR, Gravanis MB, Johnston TS. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J Heart Lung Transplant. 2002;21:530-539. (Pubitemid 34451024)
10. Mehra MR, Uber PA, Park MH, Ventura HO, Scott RL. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: Clinical and neurohormonal benefits. Transplant Proc. 2004;36: 3152-3155. (Pubitemid 41126762)
11. Taylor DO, Barr ML, Radoancevic B, Renlund DG, Mentzer RM, Smart FW, Tolman DE, Frazier OH, Young JB, VanVeldhisen P. A randomized, multi-center comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999;18: 336-345. (Pubitemid 29205269)
12. Mehra MR, Uber PA, Scott RL, Park MH. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation. 2002;74:1568-1573. (Pubitemid 36014230)
13. Baran DA, Segura L, Kushwaha S, Courtney M, Correa R, Fallon JT, Cheng J, Lansman SL, Gass AL. Tacrolimus monotherapy in adult cardiac transplant recipients: Intermediate-term results. J Heart Lung Transplant. 2001;20:59-70. (Pubitemid 32112386)
14. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ. IL-30 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001;166:3789-3796. (Pubitemid 32224903)
15. Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H. Cutting edge: Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol. 2001;167:5522-5526. (Pubitemid 33062737)
16. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol. 2001;12:2500-2506. (Pubitemid 33021129)
17. Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci U S A. 2001;98:3276-3281. (Pubitemid 32220836)
18. Dresske B, Haendschke F, Lenz P, Ungefroren H, Jenisch S, Exner B, El Mokhtari NE, Lu T, Zavazava N, Faendrich F. WOFIE stimulates regulatory T cells: A 2-year follow-up of renal transplant recipients. Transplantation. 2006;81:1549-1557. (Pubitemid 43890892)
19. Ho EK, Vlad G, Colovai A, Vasilescu ER, Schwartz J, Sondermeijer H, Burke E, Marboe CC, Itescu S, Suciu-Foca N, Mancini D. Alloantibodies in heart transplantation. Human Immunology. 2009;70:825-829.
20. Michaels PJ, Espejo ML, Kobashigawa JA, Alejos JC, Burch C, Takemoto S, Reed EF, Fishbein MC. Humoral rejection in cardiac transplantation: Risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58-69. (Pubitemid 36071418)